InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Core Viewpoint - InMed Pharmaceuticals Inc. is set to present updates on its drug development pipeline, particularly focusing on its lead program INM-901 for Alzheimer's treatment, at the Life Sciences Virtual Investor Forum on September 18, 2025 [1][4]. Group 1: Event Details - The presentation will be conducted by Eric A. Adams, the CEO of InMed, and will take place at 2:00 PM ET on September 18, 2025 [2]. - Investors can register for the event and are encouraged to schedule one-on-one meetings with the company from September 18-23 [2]. - An archived webcast of the presentation will be available for those unable to attend live [2]. Group 2: Company Overview - InMed Pharmaceuticals focuses on developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs, specifically through its pipeline targeting CB1/CB2 receptors [5]. - The company's pipeline includes three programs aimed at treating Alzheimer's, ocular, and dermatological conditions [5]. Group 3: Investor Engagement - Virtual Investor Conferences (VIC) provides a platform for companies to engage with investors in real-time, enhancing communication and access to information [6]. - VIC aims to replicate the experience of an on-site investor conference, allowing for targeted one-on-one meetings and dynamic presentations [6].